ERBB2 and breast carcinoma: The forthcoming generation of translational research investigations may integrate both venous and core biopsy samples at specified intervals to identify stable circulating biomarkers, such as miRNAs, that could signify pCR in HER2/neu overexpressing breast cancer therapy.